Mn Services Vermogensbeheer B.V. Has $8.27 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Mn Services Vermogensbeheer B.V. raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 1.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 61,900 shares of the life sciences company’s stock after buying an additional 1,000 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Illumina were worth $8,272,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Bleakley Financial Group LLC bought a new position in shares of Illumina in the 4th quarter valued at $751,000. Zacks Investment Management acquired a new position in shares of Illumina in the 3rd quarter valued at about $2,924,000. Van ECK Associates Corp lifted its stake in shares of Illumina by 17.5% in the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock valued at $20,347,000 after purchasing an additional 22,718 shares during the period. Strategic Financial Concepts LLC acquired a new position in shares of Illumina in the 4th quarter valued at about $1,464,000. Finally, Allworth Financial LP lifted its stake in shares of Illumina by 720.7% in the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock valued at $1,001,000 after purchasing an additional 6,263 shares during the period. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ILMN. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and dropped their price objective for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Royal Bank of Canada dropped their price objective on Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Canaccord Genuity Group dropped their price objective on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday, February 7th. Stephens boosted their price objective on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Finally, JPMorgan Chase & Co. upped their price target on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $155.45.

Illumina Stock Performance

ILMN stock opened at $88.74 on Friday. The firm has a market cap of $14.06 billion, a PE ratio of -11.55, a P/E/G ratio of 1.60 and a beta of 1.10. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average of $123.38 and a 200-day moving average of $132.96. Illumina, Inc. has a 12-month low of $87.50 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.